We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$287M
AUM Growth
+$36M
Cap. Flow
+$39.2M
Cap. Flow %
13.67%
Top 10 Hldgs %
59.07%
Holding
34
New
3
Increased
15
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$22.4M
2
CYTK icon
Cytokinetics
CYTK
+$16.5M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$14.6M
4
MGNX icon
MacroGenics
MGNX
+$10.2M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$3.59M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.6M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.55M
3
RLMD icon
Relmada Therapeutics
RLMD
+$5.69M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.29M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.08%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$3.41M 1.19%
+269,500
New +$3.5M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.13B
$3.41M 1.19%
186,405
+624
+0.3% +$10.7K
SPRY icon
28
ARS Pharmaceuticals
SPRY
$590M
$3M 1.05%
97,143
– –
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.63M 0.92%
250,000
– –
RLMD icon
30
Relmada Therapeutics
RLMD
$544M
– –
-161,565
Closed -$5.69M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-236,500
Closed -$5.29M
SNCE
32
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-5,000
Closed -$1.01M
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-795,868
Closed -$8.55M
FPRX
34
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-361,344
Closed -$13.6M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Commodore Capital held 34 positions worth $287M, up 14% from $251M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Commodore Capital deployed $39.2M of net new capital in Q2 2021, opening 3 new positions and adding to 15 existing holdings. Its largest new stake was Celcuity: 870,967 shares worth $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $4.59M trimmed.

  • Commodore Capital's largest Q2 2021 buy was Celcuity: 870,967 shares worth $20.9M.
  • Commodore Capital added most to Aclaris Therapeutics in Q2 2021, an estimated $14.6M increase.
  • Commodore Capital's biggest Q2 2021 reduction was Protagonist Therapeutics, cutting an estimated $4.59M.
  • Commodore Capital fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $13.6M.
  • Commodore Capital's ten largest holdings make up 59% of its $287M portfolio in Q2 2021.
  • Commodore Capital opened 3 new positions and closed 5 in Q2 2021.
  • Commodore Capital's portfolio value rose 14% quarter-over-quarter to $287M.

Based on Commodore Capital's 13F filing for Q2 2021, filed 16 Aug 2021.